Despite concerns about adverse neurocognitive events raised by prior trials, pharmacological PCSK9 (proprotein convertase subtilisin/kexin type-9) inhibition was not associated with neurocognitive effects in a recent phase 3 randomized trial. PCSK9 loss-of-function (LOF) variants that result in lifelong exposure to lower levels of low-density lipoprotein cholesterol can provide information on the potential long-term effects of lower low-density lipoprotein cholesterol on neurocognitive impairment and decline.
S
tatin therapy has been associated with neurocognitive dysfunction in some but not all studies. [1] [2] [3] The US Food and Drug Administration issued a warning about potential adverse treatment effects of statin therapy in 2012. 4 Additionally, short-term trials of pharmacological PCSK9 (proprotein convertase subtilisin/kexin type-9) inhibition to lower low-density lipoprotein cholesterol (LDL-C) suggested a possible association with neurocognitive adverse events. 5, 6 Over 26 months of follow-up, the phase 3 EBBINGHAUS trial (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects) found no difference in change over time in neurocognitive function between participants randomized to evolocumab versus a placebo in addition to standard of care. 7 Also, there were no differences in neurocognitive function between participants who achieved and did not achieve an LDL-C <25 mg/dL during follow-up. 7 Sequence variation in the PCSK9 gene is a major determinant of circulating levels of LDL-C. 8 Loss-of-function (LOF) variants in the PCSK9 gene, occurring in 1% to 3% of black adults, are associated with low circulating LDL-C concentration. 9 In a recent meta-analysis of 9 studies, 2.3% of black participants had nonsense mutations in PCSK9, which were associated with a 35 mg/dL lower LDL-C level, whereas 3.1% of white participants had sequence variation in PCSK9 that was associated with a 13 mg/dL lower LDL-C level. 10 Studying the association of PCSK9 LOF variants with neurocognitive function can provide insights into the long-term association between low LDL-C and neurocognitive function as well as the potential for neurocognitive side effects with PCSK9 inhibitors. In the current study, we examined the association of PCSK9 LOF variants and LDL-C with neurocognitive impairment and longitudinal decline in cognition among black participants ≥45 years of age in the REGARDS study (Reasons for Geographic and Racial Differences in Stroke).
METHODS
The data, analytic methods, and study materials will not be made publicly available to other researchers for purposes of reproducing the results or replicating the procedure. However, with review and approval, the information is available from the REGARDS study under established data sharing procedures.
Study Population
The REGARDS study is a prospective cohort study that enrolled black and white adults ≥45 years of age between January 2003 and 2007. 11 By design, the study oversampled black participants. Approximately half of the sample was recruited from the 8 southern US states referred to as the stroke buckle (coastal plain region of North Carolina, South Carolina, and Georgia) and stroke belt (remainder of North Carolina, South Carolina, and Georgia, plus Alabama, Mississippi, Tennessee, Arkansas, and Louisiana), with the remaining participants recruited from the rest of the continental United States. Trained and certified health professionals conducted in-home study visits at baseline that included a physical examination, blood pressure measurements, ECG, the collection of a blood sample, and a urine sample. Of relevance to the current analysis, telephone interviews with REGARDS study participants were conducted every 6 months after baseline. Starting in December 2003, brief neurocognitive screening assessments were administered annually; starting in January 2006, expanded neurocognitive assessments were administered at regular intervals on a different schedule than the screening assessments ( Figure I in the online-only Data Supplement). All neurocognitive assessments were administered during the telephone interviews.
We included black REGARDS participants who were genotyped for PCSK9 LOF variants and had blood collected during an in-home visit (n=10 695). The population for the current analysis was restricted to blacks. Only a small sample of white REGARDS participants were genotyped, and distinct PCSK9 variants are found in black and white populations; the PCSK9 LOF variants observed in black populations result in lower LDL-C levels than the PCSK9 variants observed in white populations. 10 The Institutional Review Boards of all participating institutions approved this study. All participants provided written informed consent for participation, including neurocognitive testing and genotyping.
Data Collection

Covariates
At baseline, trained interviewers conducted computer-assisted telephone interviews and an in-home examination to obtain information on participants' demographics (age, sex, region of residence, education), cigarette smoking, alcohol consumption, waist circumference, physical activity, and history of stroke, atrial fibrillation, and coronary heart disease. Blood samples were used to measure fasting total cholesterol, highdensity lipoprotein cholesterol, and triglycerides. LDL-C was
Clinical Perspective
What Is New?
• In this general population sample of black adults with extensive data collection and follow-up, there was no association between PCSK9 loss-of-function variants and neurocognitive impairment or longitudinal neurocognitive decline.
• There was no association between lower low-density lipoprotein cholesterol levels and neurocognitive impairment or decline during follow-up.
• The current study provides evidence in a contemporary population that PCSK9 loss-of-function variants and resulting lifelong exposure to lower low-density lipoprotein cholesterol levels are not associated with neurocognitive impairment and decline.
What Are the Clinical Implications?
• The results of this study suggest that lifelong exposure to low PCSK9 levels and the resulting low levels of low-density lipoprotein cholesterol do not have major effects on neurocognitive outcomes. 12 High-sensitivity C-reactive protein was measured by particle-enhanced immunonephelometry using the BNII nephelometer. The Chronic Kidney Disease Epidemiology Collaboration equation was used to calculate estimated glomerular filtration rate. 13 Urinary albumin and creatinine measures were used to calculate the albumin-to-creatinine ratio. Depressive symptoms were measured using the Center for Epidemiological Studies Depression-4 scale. Antihypertensive, statin, antidiabetic/ insulin, benzodiazepine, antipsychotic, and antidepressant medication use was identified during a medication inventory.
Genotyping
Genotyping of the variants Y142X (rs67608943) and C679X (rs28362286) single-nucleotide polymorphisms was performed at the University of Vermont using a Taqman assay on DNA that was extracted from packed white blood cells. Participants with ≥1 of either LOF variant were categorized as being carriers.
Neurocognitive Function Assessment
Verbal learning, verbal memory, and semantic fluency were assessed using tests drawn from the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) battery (Word List Learning, Word List Delayed Recall, and Semantic Animal Fluency, respectively). Global cognitive function was examined using the Six-Item Screener (SIS) assessment. As described previously, CERAD and SIS tests were administered by telephone at 18-to 24-month and 12-month intervals, respectively.
14 Neurocognitive assessment data were available through August 31, 2012. Word List Learning is the number of words recalled on a 10-item list, administered 3 times (score, 0-30). Word List Delayed Recall is the number of words remembered after a delay (score, 0-10). Semantic Animal Fluency records the number of animals named in 1 minute. Each has been validated in the identification of mild cognitive impairment, 15 dementia, and Alzheimer disease. 16 To create REGARDS-specific population norms, means and SDs on each test were calculated within 32 strata defined by age group (45-54, 55-64, 65-74, and 75+ years), sex (female, male), and education category (less than high school, high school graduate, some college, and college graduate and above). 17 The SIS was administered at baseline and annually thereafter. This test of global cognitive function 18 assesses recall ability based on a 3-item word list as well as orientation to year, month, and day of the week, and scores range from 0 to 6.
To identify neurocognitive impairment, we required participants to have completed ≥1 CERAD battery (n=7409) or SIS neurocognitive assessment (n=10 461) during the course of the study (Figure) . We applied definitions of neurocognitive outcomes previously used in REGARDS and other cohort studies. 4, 19 Neurocognitive impairment was defined as a score ≥1.5 SDs below the stratum-specific mean on 2 or 3 of the verbal learning, Word List Delayed Recall, and Semantic Animal Fluency tests from the CERAD battery at first assessment or during any follow-up assessment. 20 In a separate analysis using the SIS, neurocognitive impairment was defined as a score <5 during any assessment. 21 In a previous study, sensitivity and specificity were 74.2% and 80.2%, respectively, to identify clinically confirmed neurocognitive impairment or dementia in a community-based cohort using an SIS score <5. 21 A meta-analysis of randomized controlled trials conducted by Lipinski . While designing the current study, we conducted a priori power calculations assuming 8000 participants with ≥1 complete neurocognitive assessment, 5% prevalence of CERAD-defined neurocognitive impairment, 10% prevalence of SIS-defined neurocognitive impairment, 2.3% prevalence of PCSK9 LOF variants, and ORs of 2.0 and 2.5 ( Table I in the online-only Data Supplement). Using a χ 2 test with an α of 0.05, we estimated that we would have 74% and 92% power to detect ORs of 2.0 and 2.5, respectively, when examining CERAD-defined neurocognitive impairment and 91% and 99% power to detect ORs of 2.0 and 2.5, respectively, when examining SIS-defined neurocognitive impairment.
Statistical Analysis
We calculated means and SDs or number and proportions for participant characteristics in the overall population and among those with and without PCSK9 LOF variants. Tests of statistical significance for differences between groups were conducted using t tests for means and χ 2 tests for proportions. The presence of neurocognitive impairment at any assessment was estimated for participants with and without PCSK9 LOF variants for the CERAD-and SIS-based definitions of neurocognitive impairment, separately. Baseline characteristics of participants by CERAD-defined and, separately, SIS-defined neurocognitive impairment are provided in Tables II and III in any assessment associated with PCSK9 LOF variants were estimated using logistic regression with progressive adjustment. First, we adjusted for age at baseline and the total number of neurocognitive assessments performed. Second, we adjusted for the variables in the first model and a neurocognitive impairment risk score. Adjusting for a single score allowed us to account for potential confounders without overfitting the regression models. 23 To create this score, we calculated the probability of neurocognitive impairment at any assessment for each participant from logistic regression models, including gender; region of residence; education; waist circumference; smoking; alcohol use; physical activity; systolic and diastolic blood pressure; use of antihypertensive medication; use of benzodiazepines, antipsychotics, or antidepressants; estimated glomerular filtration rate <60 mL·min ; albuminuria; diabetes mellitus; atrial fibrillation; and depressive symptoms. In a third model, we additionally adjusted for statin use, history of coronary heart disease or stroke, and high-sensitivity C-reactive protein.
To assess differences in neurocognitive decline between participants with versus without PCSK9 LOF variants, we modeled each of the 3 CERAD and the SIS neurocognitive function assessments as separate continuous variables. These measures were standardized as z scores with a mean=0 and SD=1, where positive values indicate better performance and negative values indicate worse performance on assessments. Using a generalized linear model, we examined baseline differences in each neurocognitive domain score by PCSK9 variant status using progressive adjustment. First, we adjusted for age at baseline and the total number of neurocognitive assessments performed. Second, we adjusted for the variables in the first model and a neurocognitive impairment risk score. In a third model, we additionally adjusted for statin use, history of coronary heart disease or stroke, and high-sensitivity C-reactive protein. Next, using linear repeated measures modeling with a compound symmetry covariance structure and empirical variance estimators, we examined neurocognitive changes over time for each continuous neurocognitive domain. We included a time variable that represented the length of time from the first assessment to each follow-up assessment. Associations between PCSK9 LOF variants and neurocognitive changes from these models used all available assessments. To determine whether the rate of neurocognitive decline differed by PCSK9 variant status, we included an interaction term between time and PCSK9 variant status. Initially, time was modeled as a quadratic spline. Because these time trends appeared linear, time was modeled linearly in the final analyses. We tested whether the association between PCSK9 LOF variants and neurocognitive impairment and neurocognitive decline varied by statin use and LDL-C by including cross-product terms in the models.
Using logistic and linear regression, we also examined the association between LDL-C and neurocognitive impairment and decline, respectively. First, we adjusted for age at baseline and the total number of neurocognitive assessments performed. Second, we adjusted for the variables in the first model and a neurocognitive impairment risk score. In a third model, we additionally adjusted for statin use, history of coronary heart disease or stroke, and high-sensitivity C-reactive protein. Initially, LDL-C was modeled as a continuous variable using quadratic splines. There was no evidence that the association between LDL-C and neurocognitive impairment was nonlinear. Therefore, we modeled LDL-C as a linear continuous variable. For ease of interpretation, results are presented per 20 mg/dL LDL-C decrements.
We tested whether the association between LDL-C and neurocognitive impairment and decline differed by statin use and PCSK9 variant status by adding cross-product terms to the models. All analyses were conducted using SAS 9.4.
RESULTS
Population Characteristics
The mean age of the population at baseline was 64.1 (SD, 9.3) years, and 61.7% (n=6599) were female (Table 1). More than half of the population (51.3%) lived in the stroke belt/buckle region of the United States, and 80.5% (n=8612) of the population had at least a high school education. The CERAD battery was administered an average of 2.3 (range, 1-4) times, and the SIS was administered an average of 4.9 (range, 1-11) times over a mean follow-up of 5.6 years. Overall, 2.3% (n=241) of participants had PCSK9 LOF variants. Among participants with versus without PCSK9 LOF variants, the prevalence of diabetes mellitus was higher (35.5% versus 29.5%, P=0.05), and mean LDL-C (85 mg/dL versus 118 mg/dL, P<0.001) and prevalence of statin use (13.3% versus 29.7%, P<0.001) were lower.
PCSK9 and Neurocognitive Impairment
The prevalence of neurocognitive impairment by the CERAD definition was 6.2% and 6.0% for individuals with and without PCSK9 LOF variants, respectively (Table 2) . For the SIS definition, the prevalence of neurocognitive impairment comparing individuals with versus without PCSK9 LOF variants was 15.2% and 15.7%, respectively. In unadjusted models, the ORs for neurocognitive impairment comparing participants with versus without PCSK9 LOF variants were 1.04 (95% CI, 0.54-1.98) and 0.97 (95% CI, 0.67-1.38) using the CERAD and SIS definitions, respectively. After full multivariable adjustment, ORs for neurocognitive impairment were 1.11 (95% CI, 0.58-2.13) and 0.89 (95% CI, 0.61-1.30) when using the CERAD and SIS definitions of impairment, respectively. CERAD and SIS neurocognitive z scores were not statistically significantly different between participants with versus without PCSK9 LOF variants at baseline (Table IV in the online-only Data Supplement). In multivariable adjusted models, average standardized differences over follow-up between participants with versus without PCSK9 LOF variants were -0.02 lower (95% CI, -0.12 to 0.08) for SIS, -0.04 lower (95% CI, -0.16 to 0.09) for Word List Learning, 0.05 higher (95% CI, -0.08 to 0.18) for Word List Delayed Recall, and -0.06 lower (95% CI, -0.17 to 0.06) for Semantic Animal Fluency (Table 3) . There was no evidence that the trajectory in neurocognitive decline differed by PCSK9 variant status (ie, P>0.10 for the interaction between follow-up time and PCSK9 variant status for each neurocognitive test). The asso- 
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LDL-C and Neurocognitive Impairment
In unadjusted models, ORs for neurocognitive impairment per 20 mg/dL lower LDL-C were 1.05 (95% CI, 1.00-1.11) and 1.02 (95% CI, 0.99-1.05) for the CERAD and SIS definitions of impairment, respectively (Table 4) . After multivariable adjustment, ORs for neurocognitive impairment were 1.02 (95% CI, 0.96-1.08) and 0.99 (95% CI, 0.95-1.02) for the CERAD and SIS definitions of impairment, respectively. There were no statistically significant associations between LDL-C and baseline z scores for any CERAD or SIS assessment (Table V in the online-only Data Supplement). There was no evidence that trajectory in neurocognitive decline varied by LDL-C (P>0.10 for the interaction between follow-up time and LDL-C for each neurocognitive test).
In multivariable adjusted models, average standardized differences over follow-up for 20 mg/dL lower LDL-C were 0.01 higher (95% CI, 0.00-0.02) for SIS and 0.00 (95% CI, -0.01 to 0.01) for each CERAD assessment (Word List Learning, Word List Delayed Recall, and Semantic Animal Fluency) ( Table 5 ). The association between each 20 mg/ dL lower LDL-C and neurocognitive impairment and, separately, neurocognitive decline did not vary by statin use or PCSK9 LOF variant status (all P values >0.05).
DISCUSSION
In the current study of middle and older-aged blacks, there was no association between having PCSK9 LOF variants and neurocognitive impairment based on the CERAD battery and SIS assessments. PCSK9 LOF variants were not associated with longitudinal changes in neurocognitive function. Additionally, LDL-C was not associated with neurocognitive impairment or decline after adjusting for risk factors for neurocognitive impairment. The results from the current study provide evidence in a contemporary population that PCSK9 LOF variants and resulting lifelong exposure to lower LDL-C levels are not associated with neurocognitive impairment and decline. Findings from the current study are consistent with a secondary analysis of the PROSPER trial (Prospective Study of Pravastatin in the Elderly at Risk), which reported that lower cholesterol levels because of PCSK9 LOF variants were not associated with cognitive performance. 24 However, differences between the PROSPER trial and the current study should be noted. PROSPER enrolled men and women between 70 and 82 years of age, 25 whereas the REGARDS study enrolled men and women ≥45 years of age. Additionally, the current analysis was restricted to blacks because of a small number of white participants in the REGARDS study who have been genotyped and have PCSK9 LOF variants (n=21). 10 The PROSPER trial also administered different cognitive function assessments than were administered in the REGARDS study. In the PROSPER trial, cognitive tests assessed verbal learning, delayed recall, selective attention, and processing speed, whereas in the REGARDS study, verbal learning, verbal memory, semantic fluency, and global cognition were assessed. The PROSPER trial did not enroll individuals with a low cognitive function score at baseline. 26 The REGARDS study did not exclude individuals with low cognitive scores at baseline but did exclude individuals who, in the judgment of an interviewer, could not participate meaningfully in study interviews (eg, those with impaired comprehension). Finally, different PCSK9 variants are present in white compared with black populations and were examined in PROSPER. Despite these differences, the overall conclusions are comparable between the 2 studies.
Evidence from observational studies on the association between low LDL-C and worse neurocognitive function has been conflicting. 27, 28 For example, in an older cohort, high LDL-C was associated with better overall memory scores. 27 A secondary analysis of 2 Danish general population studies found that low LDL-C levels were associated with an increased risk of Alzheimer disease. 29 However, low cholesterol levels because of PCSK9 variants had no association with the risk of Alzheimer disease. In contrast, older adults in the Northern Manhattan Study with high LDL-C had an increased risk of vascular dementia. 30 The association between low LDL-C and neurocognitive function in older populations is difficult to interpret because aging is associated with both higher LDL-C and lower cognition. 
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The current study provides contemporary evidence for these associations in a population of middle-age and older adults. PCSK9 has an important role in regulating circulating LDL-C levels. Sequence variations in the PCSK9 gene causing LOF mutations are associated with lower levels of LDL-C and a reduced risk of coronary heart disease. 8, 10 In several case reports/series, reductions in LDL-C after the initiation of statin therapy have been associated with neurocognitive impairment. [1] [2] [3] However, these were often based on consumer reporting and rarely accompanied by formal neurocognitive testing. Neurocognitive symptoms in people taking statins have usually been mild and reversible, and these deficits resolved after treatment discontinuation. 1 In the current study, there was no association between PCSK9 LOF variants and neurocognitive impairment or decline in participants taking or not taking statins. There was also no association between LDL-C and neurocognitive impairment or decline in this subgroup. This finding is consistent with trials monitoring adverse neurocognitive events associated with statin therapy alone 25, 32 or in combination with PCSK9 inhibitors. 33, 34 Imbalances in neurocognitive events, including delirium, cognitive and attention disorders and disturbances, dementia and amnestic conditions, disturbances in thinking and perception, and mental impairment disorders, were reported in post hoc analyses of short-term phase 2 and 3 clinical trials of PCSK9 inhibitors. 5, 6 A combined analysis of the open-label, shorter-duration evolocumab trials (median follow-up time, 11.1 months) reported a higher frequency of neurocognitive adverse events in participants randomized to the treatment arms (n=27, 0.9%) compared with their counterparts randomized to placebo (n=4, 0.3%). 5 However, participants in the treatment arms received more face-to-face follow-up visits, providing additional opportunity to detect adverse events. In the ODYSSEY LONG TERM trial (Long-Term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Ad- Model 1 includes adjustment for age. Model 2 includes adjustment for variables in model 1 plus a propensity score (sex, region of residence, education, waist circumference, smoking, alcohol use, physical activity, systolic and diastolic blood pressure, antihypertensive medication use, psychiatric medication use, estimated glomerular filtration rate, albuminuria, diabetes mellitus, atrial fibrillation, and depressive symptoms). Model 3 includes adjustment for variables in model 2 plus statin use, history of coronary heart disease, history of stroke/transient ischemic attack, and high-sensitivity C-reactive protein. CERAD indicates Consortium to Establish a Registry for Alzheimer's Disease; CI, confidence interval; LOF, loss of function; PCSK9, proprotein convertase subtilisin/kexin type-9; and SIS, Six-Item Screener.
*z Score differences among participants with versus without LOF variants were calculated using all available assessments. †P value testing for the average differences in neurocognitive z scores comparing participants with versus without PCSK9 LOF variants.
Circulation. The results from these 2 clinical trials could be related to chance because the total number of neurocognitive outcomes was small (31 in evolocumab trials and 22 in alirocumab trials). Additionally, neurocognitive events were not verified against standard definitions. A meta-analysis of 17 randomized clinical studies with a maximum duration of 102 weeks found an increased risk of neurocognitive adverse events among those randomized to receive PCSK9 inhibitors versus ezetimibe or placebo. 22 In contrast, a pooled analysis of data from 14 randomized trials of PCSK9 inhibitors found that alirocumab treatment compared with ezetimibe or placebo did not result in an imbalance of neurocognitive adverse events over a median follow-up of 1.5 years. 33 Neurocognitive impairment was not more common in participants achieving low levels of LDL-C (<25 mg/dL versus ≥25 mg/dL). 33 The Battery to examine working memory, memory function, and psychomotor speed, there was no evidence of an association between pharmacological PCSK9 inhibition or low LDL-C with neurocognitive decline. 7 The results from the current study complement results from EBBINGHAUS by examining the cumulative effects of exposure to low levels of LDL-C during a lifetime, despite using different tests of neurocognitive function.
Strengths of the current study include the use of validated and detailed CERAD assessments of neurocognitive function across domains 20 that have been consistently associated with performance on cognitively demanding activities of daily living. 35, 36 The SIS is also a validated measure. 21 The positive and negative predictive values for neurocognitive impairment and dementia as determined by a SIS score <5 are 100% and 76.6%, respectively. 21 Additionally, the REGARDS study had few exclusion criteria and enrolled participants without regard to LDL-C levels, statin use, and prevalent cardiovascular disease. We also acknowledge some limitations. This analysis was restricted to black participants, limit- *z Score differences among participants with versus without LOF variants were calculated using all available assessments. †P value testing for the average differences in neurocognitive z scores associated with 20 mm Hg lower LDL-C.
ing the generalizability of the findings. Even considering the older mean age of the population at baseline (64 years), the average duration of participant follow-up (5.6 years) may limit our ability to detect neurocognitive impairment occurring later in life. Because neurocognitive assessments were administered in ≈1-year (SIS) or 2-year (CERAD) cycles and some participants had neurocognitive impairment at the first assessment, we were unable to determine the time at which a participant became impaired. Additionally, the number of neurocognitive assessments administered varied across participants. The prevalence of PCSK9 LOF variants was low (2.3%), and few participants with PCSK9 LOF variants were categorized as having either CERAD-or SIS-defined neurocognitive impairment, which limited our power to detect small to moderate differences in risk of neurocognitive impairment. Although validated, the CERAD battery and SIS may miss subtle but clinically important neurocognitive deficits. This study examined neurocognitive impairment and decline; we do not have information on the full range of neurocognitive adverse events reported in the clinical trials of PCSK9 inhibitors. We relied on several self-reported covariates that may result in misclassification. Finally, examination measurements and laboratory data were available from only a single study visit, so we could not account for day-to-day variation in covariates.
In conclusion, PCSK9 LOF variants were not associated with neurocognitive impairment among a general population sample of middle-age and older blacks. No association was present for the overall population and for participants taking and not taking statins. Also, lower LDL-C levels were not associated with neurocognitive impairment. The results of this study suggest that lifelong exposure to low PCSK9 levels and the resulting low levels of LDL-C do not have major effects on neurocognitive outcomes. 
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